dynorphin (1-8) has been researched along with malondialdehyde in 1 studies
| Studies (dynorphin (1-8)) | Trials (dynorphin (1-8)) | Recent Studies (post-2010) (dynorphin (1-8)) | Studies (malondialdehyde) | Trials (malondialdehyde) | Recent Studies (post-2010) (malondialdehyde) |
|---|---|---|---|---|---|
| 173 | 0 | 3 | 27,849 | 1,405 | 13,922 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Cheng, Y; Du, S; Fan, J; Ma, S; Qu, H; Shi, J; Sun, H; Yao, Q; Zhan, S; Zhang, M; Zhang, X | 1 |
1 other study(ies) available for dynorphin (1-8) and malondialdehyde
| Article | Year |
|---|---|
Dynorphin A (1-8) inhibits oxidative stress and apoptosis in MCAO rats, affording neuroprotection through NMDA receptor and κ-opioid receptor channels.
Topics: Animals; Apoptosis; Blood-Brain Barrier; Caspase 3; Dynorphins; Infarction, Middle Cerebral Artery; Malondialdehyde; Neuroprotective Agents; Oxidative Stress; Peptide Fragments; Rats; Receptors, N-Methyl-D-Aspartate; Receptors, Opioid, kappa; Superoxide Dismutase | 2021 |